Singapore, Singapore, March 24, 2016 --(PR.com
)-- The 3rd MEDLAB Asia Pacific Exhibition and Conference, organised by Informa Life Sciences Exhibitions commenced today and will continue until March 24 2016. It is held at the Sands Expo and Convention Centre, Singapore. The conference programme will featured in total nine CME-accredited conference tracks, accredited by the Singapore Medical Council. The exhibition will feature some of the key industry leaders such as, BioMerieux, Bio-Rad, EUROIMMUN, Siemens, Abbott, Sysmex Mindray, and Snibe to name a few.
The exhibitors showcased some of their latest advanced products and services to an audience of laboratory specialists, and healthcare professionals. BioMerieux unveiled a series of new solutions providing efficient results, such as The FilmArray® Meningitis-Encephalitis Panel enabling rapid and accurate automated testing for the 14 most common pathogens responsible for community acquired meningitis or encephalitis including viruses, bacteria and yeast, which leads to better patient care. Sysmex showcased Sysmex’s Urinalysis modular system and Sysmex-Hyphen Bio-Med anticoagulant reagents. Sysmex Urinalysis modular concept provides a smart walkaway system to improve workflow and productivity. Sysmex-Hyphen Bio-Med anticoagulant reagent portfolio offers laboratories with a complete testing range for direct oral anticoagulants (DOACs) assays.
“MEDLAB Asia Pacific continues to be the optimum platform for the laboratory and healthcare industry in the Asia Pacific region to come together in order to exchange knowledge, and showcase scientific finding, instruments, products, and services. This exemplary event is only expected to grow exponentially from here,” highlighted Simon Page, Managing Director, Informa Life Sciences Exhibitions.
Bio-Rad Laboratories launched for the first time in South East Asia, their next generation of A1c testing equipment - D100. This technology, combined, improved HPLC accuracy and precision, high-throughput capacity, and simplified results review.
The Zika Virus has been one of the most talked about concerns in the healthcare industry, EUROIMMUN AG, a manufacturer of test systems and instruments for medical diagnostics, has developed the first commercial CE-IVD marked serological detection of Zika virus infections. The ELISA and indirect immunofluorescence tests from EUROIMMUN enable the determination of specific antibodies (IgM, IgG) against the virus is now available as CE-IVD marked. These tests are currently used in clinical study at the Fiocruz (Fundação Oswaldo Cruz), an institute linked to the Brazilian Ministry of Health.
“Our ELISAs are based on very specific, recombinant antigens which are produced in EUROIMMUN research laboratories. Positive results are a clear indicator of a Zika virus infection and the immunofluorescence mosaics help laboratory physicians to investigate patient samples for other viral fever diseases in parallel. This is important for differential diagnosis, since in Latin America there are also dengue and chikungunya viruses, which cause similar symptoms and are transmitted by the same species of mosquitoes as the Zika virus. We hope our test systems can help to clarify as soon as possible whether there is a link between the cases of microcephaly and Zika infections,” says Katja Steinhagen, head of the ELISA Infectious Serology department at EUROIMMUN AG.